Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Moodys
Boehringer Ingelheim
Baxter
McKesson

Last Updated: December 8, 2019

DrugPatentWatch Database Preview

Patent: 9,732,055

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,732,055
Title:Compositions and methods for cancer treatment
Abstract: The present invention relates to the composition and methods of use of Stat3 pathway inhibitors or cancer stem cell inhibitors in combination treatment of cancer.
Inventor(s): Li; Chiang Jia (Cambridge, MA), Mikule; Keith (Norwood, MA), Li; Youzhi (Westwood, MA)
Assignee: Boston Biomedical, Inc. (Cambridge, MA)
Application Number:12/677,516
Patent Claims:see list of patent claims

Details for Patent 9,732,055

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial Boston Biomedical, Inc. (Cambridge, MA) 2027-09-10 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 003 2006-09-27   Start Trial Boston Biomedical, Inc. (Cambridge, MA) 2027-09-10 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 002 2006-09-27   Start Trial Boston Biomedical, Inc. (Cambridge, MA) 2027-09-10 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27   Start Trial Boston Biomedical, Inc. (Cambridge, MA) 2027-09-10 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial Boston Biomedical, Inc. (Cambridge, MA) 2027-09-10 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 9,732,055

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
Express Scripts
Baxter
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.